Treatment issues in clear cell carcinoma of the ovary: A different entity?

Oncologist

Volumn 11, Issue 10, 2006, Pages 1089-1094

  Pectasides, Dimitrios ^a,b   Pectasides, Eirini ^a   Psyrri, Amanda ^a   Economopoulos, Theofanis ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Gravias 5B   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; NEDAPLATIN; PACLITAXEL; PLATINUM DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CLEAR CELL CARCINOMA; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE; TUMOR VOLUME;

ADENOCARCINOMA, CLEAR CELL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SURVIVAL RATE;

EID: 33751248513     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-10-1089     Document Type: Review

References (54)

1. Greenlee RT, Hill-Harmon MB, Murray T et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Balvert-Locht HR, Coebergh JW, Hop WC et al. Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study. Gynecol Oncol 1991;42:3-8.
3. Einhorn N, Nilsson B, Sjovall K. Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population. Cancer 1985;55:2019-2025.
4. Swenerton KD, Hislop TG, Spinelli J et al. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 1985;65:264-270.
5. Boente MP, Schilder R, Ozols RF. Gynecologic cancers. Cancer Chemother Biol Response Modif 1997;17:536-561.
6. Serov SF, Scully RE, Sobin LH. International Histological Classification of Tumors, Number 9. Histologic Typing of Ovarian Tumors. Geneva: World Health Organization 1973:1-7.
7. Aure JC, Hoeg K, Kolstad P. Mesonephroid tumors of the ovary. Clinical and histopathologic studies. Obstet Gynecol 1971;37:860-867.
8. Kennedy AW, Biscotti CV, Hart WR et al. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989;32:342-349.
9. Crozier MA, Copeland LJ, Silva EG et al. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol 1989;35:199-203.
10. Omura GA, Brady MF, Homesley HD et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9:1138-1150.
11. O'Brien ME, Schofield JB, Tan S et al. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 1993;49):250-254.
12. Jenison EL, Montag AG, Griffiths CT et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989;32:65-71.
13. Goff BA, Sainz de la Cuesta R, Muntz HG et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996;60:412-417.
14. Behbakht K, Randall TC, Benjamin I et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998;70:255-258.
15. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-2589.
16. Ohkawa K, Amasaki H, Terashima Y et al. Clear cell carcinoma of the ovary: light and electron microscopic studies. Cancer 1977;40:3019-3029.
17. Yoonessi M, Weldon D, Satchidand SK et al. Clear cell ovarian adenocarcinoma. J Surg Oncol 1984;27:289-297.
18. Recio FO, Piver MS, Hempling RE et al. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996;78:2157-2163.
19. Nishino K, Aoki Y, Amikura T et al. Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma. Gynecol Oncol 2005;97:893-897.
20. Kennedy AW, Markman M, Biscotti CV et al. Survival probability in ovarian clear cell adenocarcinoma. Gynecol Oncol 1999;74:108-114.
21. Pather S, Quinn MA. Clear-cell cancer of the ovary - is it chemosensitive? Int J Gynecol Cancer 2005;15:432-437.
22. Skirnisdottir I, Seidal T, Karlsson MG et al. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II. Int J Oncol 2005;26:177-183.
23. Hameed K, Burslem MR, Tupper WR. Clear cell carcinoma of the ovary. Cancer 1969;24:452-459.
24. Shevchuk MM, Winkler-Monsanto B, Fenoglio CM et al. Clear cell carcinoma of the ovary: a clinicopathologic study with review of the literature. Cancer 1981;47:1344-1351.
25. Kishikawa T, Sakamoto M, Ino Y et al. Two distinct patterns of peritoneal involvement shown by in vitro and in vivo ovarian cancer dissemination models. Invasion Metastasis 1995;15:11-21.
26. Hreshchyshyn MM, Park RC, Blessing JA et al. The role of adjuvant therapy in stage I ovarian cancer. Am J Obstet Gynecol 1980;138:139-145.
27. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
28. Norris HJ, Robinowitz M. Ovarian adenocarcinoma of mesonephric type. Cancer 1971;28:1074-1081.
29. Makar AP, Baekelandt M, Trope CG et al. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995;56:175-180.
30. Pectasides D, Fountzilas G, Aravantinos G et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 2006;102:285-291.
31. Gorai I, Nakazawa T, Miyagi E et al. Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. Gynecol Oncol 1995;57:33-46.
32. Hoskins WJ, Bundy BN, Thigpen JT et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-166.
33. Ho CM, Chien TY, Shih BY et al. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol 2003;88:394-399.
34. Ho CM, Huang YJ, Chen TC et al. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 2004;94:197-203.
35. Andrews PA, Velury S, Mann SC et al. cis-Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1988;48:68-73.
36. Kasahara K, Fujiwara Y, Nishio K et al. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 1991;51:3237-3242.
37. Kigawa J, Minagawa Y, Cheng X et al. Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer. Clin Cancer Res 1998;4:1737-1741.
38. Itamochi H, Kigawa J, Akeshima R et al. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology 2002;62:349-353.
39. Itamochi H, Kigawa J, Sugiyama T et al. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002;100:281-287.
40. Nishida M. Chemosensitivity of ovarian clear cell carcinoma in vitro. Oncol Chemother 1992;8:128-136. Japanese.
41. Ohta I, Gorai I, Miyamoto Y et al. Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells. Cancer Lett 2001;162:39-48.
42. Reed E, Yu JJ, Davies A et al. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res 2003;9:5299-5305.
43. Adachi S, Ogasawara T, Yamasaki N et al. A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. Jpn J Clin Oncol 1999;29:434-437.
44. Shimizu Y, Umezawa S, Hasumi K. A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singapore 1998;27:650-656.
45. Shimizu Y, Nagata H, Kikuchi Y et al. Cytotoxic agents active against mucinous adenocarcinoma of the ovary. Oncol Rep 1998;5:99-101.
46. Tanaka T, Umesaki N, Ogita S. Camptothecin and mitomycin combination chemotherapy on ovarian clear cell carcinoma with multiple systemic metastases. Eur J Gynaecol Oncol 2000;21:377-379.
47. Nishida M, Tsunoda H, Ichikawa Y et al. Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma. Int J Clin Oncol 2004;9:403-405.
48. Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol 2003;202:97-99.
49. Nakayama K, Takebayashi Y, Nakayama S et al. Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin. Cancer Lett 2003;192:227-235.
50. Pieretti M, Hopenhayn-Rich C, Khattar NH et al. Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 2002;20:11-23.
51. Tsuda H, Bandera CA, Birrer MJ et al. Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. Oncology 2004;67:291-299.
52. Tanabe H, Nishii H, Sakata A et al. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma. Gynecol Oncol 2004;94:735-739.
53. Cai KQ, Albarracin C, Rosen D et al. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol 2004;35:552-559.
54. Tsuchiya A, Sakamoto M, Yasuda J et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003;163:2503-2512.